MX2021006681A - Anticuerpos anti-claudina y usos de los mismos. - Google Patents
Anticuerpos anti-claudina y usos de los mismos.Info
- Publication number
- MX2021006681A MX2021006681A MX2021006681A MX2021006681A MX2021006681A MX 2021006681 A MX2021006681 A MX 2021006681A MX 2021006681 A MX2021006681 A MX 2021006681A MX 2021006681 A MX2021006681 A MX 2021006681A MX 2021006681 A MX2021006681 A MX 2021006681A
- Authority
- MX
- Mexico
- Prior art keywords
- claudin
- antibodies
- antibody
- methods
- claudin antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/119797 | 2018-12-07 | ||
| PCT/CN2019/123588 WO2020114480A1 (en) | 2018-12-07 | 2019-12-06 | Anti-claudin antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021006681A true MX2021006681A (es) | 2021-11-17 |
Family
ID=70975310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006681A MX2021006681A (es) | 2018-12-07 | 2019-12-06 | Anticuerpos anti-claudina y usos de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210380680A1 (https=) |
| EP (1) | EP3891183A4 (https=) |
| JP (1) | JP7458399B2 (https=) |
| KR (1) | KR20210100655A (https=) |
| CN (1) | CN113423735B (https=) |
| AU (1) | AU2019391204A1 (https=) |
| BR (1) | BR112021011014A2 (https=) |
| CA (1) | CA3122135A1 (https=) |
| IL (1) | IL283754A (https=) |
| MX (1) | MX2021006681A (https=) |
| SG (1) | SG11202105885WA (https=) |
| WO (1) | WO2020114480A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12297265B2 (en) | 2018-12-28 | 2025-05-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody and use thereof |
| CA3128502A1 (en) | 2019-02-01 | 2020-08-06 | Novarock Biotherapeutics, Ltd. | Anti-claudin 18 antibodies and methods of use thereof |
| CN115943162A (zh) * | 2020-06-19 | 2023-04-07 | 信达生物制药(苏州)有限公司 | 抗Claudin18.2抗体以及其用途 |
| CN113929780A (zh) * | 2020-07-13 | 2022-01-14 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
| KR20230079096A (ko) * | 2020-09-30 | 2023-06-05 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항체-약물 접합체를 포함하는 약제학적 조성물 및 약제학적 조성물의 용도 |
| US20240034784A1 (en) * | 2020-09-30 | 2024-02-01 | Nanjing GenScript Biotech Co., Ltd. | Antibodies targeting human claudin 18.2 and uses thereof |
| CN115109154A (zh) * | 2021-03-17 | 2022-09-27 | 三优生物医药(上海)有限公司 | 一种靶向cldn18.2的抗体或其抗原结合片段及其应用 |
| CN115611983A (zh) * | 2021-07-14 | 2023-01-17 | 三优生物医药(上海)有限公司 | Cldn18.2结合分子及其用途 |
| WO2023066267A1 (en) * | 2021-10-19 | 2023-04-27 | Biosion Inc. | Antibodies binding cldn18.2 and uses thereof |
| CN114044822B (zh) * | 2021-10-28 | 2023-06-27 | 杭州博茵生物技术有限公司 | 血清淀粉样蛋白a抗体的重链和轻链可变区、抗体及运用 |
| CN118139888A (zh) * | 2021-11-05 | 2024-06-04 | 正大天晴药业集团股份有限公司 | 抗cldn18.2抗体及其用途 |
| CN114395040B (zh) * | 2022-02-09 | 2023-12-15 | 东南大学附属中大医院 | 再生蛋白reg1a单克隆抗体及其应用 |
| WO2023196882A1 (en) | 2022-04-06 | 2023-10-12 | Zai Lab (Us) Llc | Claudin 18.2 immunohistochemistry assay and use thereof |
| CN117229398A (zh) * | 2022-06-15 | 2023-12-15 | 中山康方生物医药有限公司 | 抗cldn18.2抗体、其药物组合物及用途 |
| CA3261520A1 (en) * | 2022-07-08 | 2024-01-11 | Telix Targeting Technologies, Inc. | ANTIBODIES, THEIR MANUFACTURING PROCESSES AND METHODS OF USE |
| WO2024131683A1 (zh) * | 2022-12-19 | 2024-06-27 | 华润生物医药有限公司 | 结合cldn18.2的抗体和抗体药物偶联物及其用途 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004024617A1 (de) * | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| AU2017294276B2 (en) * | 2016-07-08 | 2024-08-01 | Crage Medical Co., Limited | Antibody for anti-claudin 18A2 and use thereof |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
-
2019
- 2019-12-06 JP JP2021532180A patent/JP7458399B2/ja active Active
- 2019-12-06 WO PCT/CN2019/123588 patent/WO2020114480A1/en not_active Ceased
- 2019-12-06 MX MX2021006681A patent/MX2021006681A/es unknown
- 2019-12-06 SG SG11202105885WA patent/SG11202105885WA/en unknown
- 2019-12-06 CN CN201980088317.6A patent/CN113423735B/zh active Active
- 2019-12-06 CA CA3122135A patent/CA3122135A1/en active Pending
- 2019-12-06 US US17/311,307 patent/US20210380680A1/en not_active Abandoned
- 2019-12-06 KR KR1020217020208A patent/KR20210100655A/ko not_active Ceased
- 2019-12-06 AU AU2019391204A patent/AU2019391204A1/en not_active Abandoned
- 2019-12-06 BR BR112021011014-3A patent/BR112021011014A2/pt not_active IP Right Cessation
- 2019-12-06 EP EP19893031.5A patent/EP3891183A4/en not_active Withdrawn
-
2021
- 2021-06-06 IL IL283754A patent/IL283754A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL283754A (en) | 2021-07-29 |
| KR20210100655A (ko) | 2021-08-17 |
| SG11202105885WA (en) | 2021-07-29 |
| CN113423735A (zh) | 2021-09-21 |
| JP7458399B2 (ja) | 2024-03-29 |
| CN113423735B (zh) | 2024-02-13 |
| BR112021011014A2 (pt) | 2021-08-31 |
| CA3122135A1 (en) | 2020-06-11 |
| EP3891183A1 (en) | 2021-10-13 |
| WO2020114480A1 (en) | 2020-06-11 |
| JP2022512132A (ja) | 2022-02-02 |
| AU2019391204A1 (en) | 2021-06-24 |
| US20210380680A1 (en) | 2021-12-09 |
| EP3891183A4 (en) | 2022-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006681A (es) | Anticuerpos anti-claudina y usos de los mismos. | |
| PH12021550152A1 (en) | Anti-cd112r compositions and methods | |
| MY207121A (en) | Anti-ror antibody constructs | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| ZA202006859B (en) | Antibodies specific for gucy2c and uses thereof | |
| MX2024015039A (es) | Composiciones anti-cd24 y usos de las mismas | |
| MX2021002415A (es) | Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas. | |
| WO2019178269A3 (en) | Antibodies that bind cd39 and uses thereof | |
| PH12020551865A1 (en) | Anti-msr1 antibodies and methods of use thereof | |
| NZ762505A (en) | Antibody-pyrrolobenzodiazepine derivative conjugate | |
| WO2018170338A3 (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| SG11201900171QA (en) | Antibody for anti-claudin 18a2 and use thereof | |
| AU2018263868A1 (en) | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies | |
| PH12021550611A1 (en) | Interleukin 10 Conjugates and Uses Thereof | |
| SA520412283B1 (ar) | Cd22 أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ | |
| MY196631A (en) | Antibody Agents Specific for Human Cd19 and uses Thereof | |
| PH12021550289A1 (en) | Ox40-binding polypeptides and uses thereof | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| BR112021016056A2 (pt) | Anticorpos de claudina 6 e usos dos mesmos | |
| EA202191257A1 (ru) | Противораковая терапия на основе иммуноцитов, связывающих liv1 | |
| ZA202103867B (en) | Tubulysins and protein-tubulysin conjugates | |
| WO2018069871A3 (en) | Anti-kras binding proteins | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| BR112021025699A2 (pt) | Anticorpos anti-mesotelina e imunoconjugados dos mesmos | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения |